“Duration of Anti-PD-1 Therapy in Metastatic Melanoma (STOP-GAP)”
The purpose of this study is to compare the effects on patients with metastatic melanoma of taking a government approved and paid-for PD-1 inhibitor intermittently, with taking the same type of agent continuously. Researchers want to see if the two ways of giving this type of treatment work equally well in extending the life of patients with melanoma, or not.
Drug - Intermittent PD-1 inhibitor therapy
Drug - Continuous PD-1 inhibitor therapy
A Randomized Phase III Trial of the Duration of Anti-PD-1 Therapy in Metastatic Melanoma (STOP-GAP)